This inventor holds 245 USPTO granted patents and 84 published patent applications, plus 20 CIPO patents and 52 EPO patents, primarily in Cancer Genomics (CPC class C12Q2600-156). Top assignees: Johns Hopkins University, Duke University, University of Utah Research Foundation. Active years: 1993-2026.
Inventors with similar research interests:
Location History:
- Balitmore, MD (US) (2017)
- Baltimore, MD (US) (1993 - 2024)
Company Filing History:
235 out of 3,794 
18 out of 2,074 
12 out of 1,685 
Years Active: 1993-2026
Areas of Expertise:
Title: Bert Vogelstein: Unraveling the Secrets of Tumor Suppressor Genes
Introduction:
In the realm of cancer research, few individuals have made as profound an impact as Bert Vogelstein. Hailing from Baltimore, MD (US), Vogelstein has dedicated his career to the discovery of tumor suppressor genes – essential components in the fight against cancer. This article delves into his remarkable achievements, latest patents, career highlights, and noteworthy collaborations, shedding light on his invaluable contributions to this field.
Latest Patents:
Vogelstein's recent patents include groundbreaking research on checkpoint blockade and microsatellite instability. Specifically, he has explored the use of inhibitory antibodies targeting immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1). These studies have shown tremendous promise in breaking immune tolerance and promoting anti-tumor immunity, particularly in patients with a certain category of tumor. This innovative approach holds potential for more effective cancer treatments.
Career Highlights:
Throughout his distinguished career, Bert Vogelstein has held prominent positions at prestigious institutions. He has made significant contributions at The Johns Hopkins University and Duke University, where his work continues to impact the field of cancer research. With an impressive portfolio of 225 patents, Vogelstein's focus on the discovery and understanding of tumor suppressor genes has garnered global recognition.
Collaborations:
Vogelstein's collaborative efforts have amplified the impact of his research. Two notable coworkers who have played a pivotal role in his work are Kenneth W Kinzler and Nickolas Papadopoulos. Their combined expertise and dedication have contributed to groundbreaking discoveries in the realm of tumor suppressor genes. These collaborations have strengthened the scientific community's understanding of cancer and opened avenues for novel treatments.
Conclusion:
Bert Vogelstein's relentless pursuit of knowledge and unrivaled dedication to cancer research has revolutionized our understanding of tumor suppressor genes. His latest patents on checkpoint blockade and microsatellite instability reveal the potential for more effective and targeted cancer treatments. Collaborations with exceptional individuals such as Kenneth W Kinzler and Nickolas Papadopoulos have propelled his research forward. Vogelstein's work continues to inspire and pave the way for future innovations in the fight against cancer.
Please note: For more detailed information regarding Bert Vogelstein's patents, career, and collaborations, we recommend visiting idiyas.com, an innovative platform dedicated to showcasing the world of innovations and patents.